블로그
- Emergent Local Lorentz Symmetry:Reconciling Causal Set Rigidity with Continuum Invariance.Minhee Lee Emergent Local Lorentz Symmetry: Reconciling Causal Set Rigidity with Continuum Invariance Minhee Lee the rigidity of sprinkled causal sets — showing that generic realizations possess almost surely no non-trivial
- [영어 회화] Encounter Class 59 Feedback You could then describe the accomodations with words like "modern" and "old-fashioned". with "which" and "who".
- 800G-OSFP NVIDIA 호환모듈 QM9790 is part of the Quantum-2 platform and offers 64 NDR 400Gb/s InfiniBand ports in a 1U design, with 32 OSFP ports and 51.2Tb/s non-blocking switching capacity, making it a strong fit for AI and HPC environments
- 벨기에 DOUBLE AXE GATE- Double Bar Yellow Self Closing Safety Gate opening angle of 180 degrees allows for easier access High visibility safety yellow colour (RAL 1023) Non-corroding steel components Very strong construction Long design life with 5 years (100,000 cycles) warranty U.
- [LTspice] 8. MOSFET (5) SPICE Model Level 2 — DC Currents the following additional phenomena: The depletion layer between the channel and substrate is treated with a non-uniform charge distribution.
- 힙합 매거진 HAUS OF MATTERS & w/HAUS OF MATTERS 25년 10월호 발간! ISSUE 29 (25.10) -목차- / New Releases 리치 이기 [Mazrin] 지넥스 [ETERNAL] 자이언티 [POSER] NSW 윤 [IVY] (Interview with NSW 윤) 크러쉬 [FANG] 샤이보이토비, 우슬라임 - [Bookkyungbanjeom] 블라세 [SELF MADE] 히피쿤다 [TUNDRA] 올웨이즈캐핑보이 & 서프 [Non-Fiction
- 릴리 경구GLP1제제, Orforglipron 3상 연구 발표 Phase 3 ATTAIN-1 trial of orforglipron (oral GLP-1 agonist): 릴리에서 개발한 경구용 non-peptide 약제인 올포글리프론 3상 임상시험 −11.2% weight loss at 72 weeks with highest dose vs. −2.1% with placebo >50% of patients hit ≥10%
- onedrive 싱크 OneDrive To enable and start the OneDrive systemd service (with notifications enabled) for your current (non-root
- Breaking the Sorting Barrier for Directed Single-Source Shortest Paths We give a deterministic -time algorithm for single-source shortest paths (SSSP) on directed graphs with real non-negative edge weights in the comparison-addition model.
- A Bayesian network meta-analysis of EGFR-tyrosine kinase inhibitor treatments in patients with ... A Bayesian network meta-analysis of EGFR-tyrosine kinase inhibitor treatments in patients with EGFR mutation-positive non-small cell lung cancer Background To date, no direct comparisons have been performed to compare